---
figid: PMC8971810__fphys-13-816218-g004
figtitle: 'C1q/Tumor Necrosis Factor-Related Protein 9: Basics and Therapeutic Potentials'
organisms:
- Homo sapiens
- Macaca mulatta
- Pan troglodytes
- Oreochromis niloticus
- Epinephelus coioides
- Eudontomyzon morii
- Mus musculus
- Rattus norvegicus
- Adenoviridae
- Human immunodeficiency virus
- Apostichopus japonicus
organisms_ner:
- Macaca mulatta
- Pan troglodytes
- Homo sapiens
- Mus musculus
- Rattus norvegicus
- Oreochromis niloticus
- Drosophila melanogaster
- Danio rerio
pmcid: PMC8971810
filename: fphys-13-816218-g004.jpg
figlink: /pmc/articles/PMC8971810/figure/F4/
number: F4
caption: 'Signaling pathways regulated by CTRP9. CTRP9 binds and affects four receptors
  on the cell membrane and activates downstream signaling pathways: (1) LPS binds
  to membrane receptor CD14 to activate the TLR4 signaling pathway. IκBs bind to NFκB
  to promote the expression of downstream inflammatory genes, including MCP-1, TNF-α,
  ICAM-1, and VCAM-1. CTRP9 blocks the activation of TLR4 receptors via LPS. (2) CTRP9
  associates with IFNγ to activate the JAK/STAT3 pathway, thus upregulating the gene
  and protein expression of iNOS. (3) CTRP9 associates with AdipoR1 to upregulate
  the SIRT1/PGC1α/AMPK pathway, activate ACC and inhibit the expression of nuclear
  transcription factor NFκB, upregulate LXRα and promote the expression of ABCA1,
  and upregulate ABCG1 to activate Akt, thereby increasing eNOS expression; (4) CTRP9
  associates with N-cadherin to activate ERK1/2 and upregulate MMP-9 and Nrf2. AMPK,
  AMP-activated protein kinase; CD14, cluster of differentiation 14; eNOS, endothelial
  nitric oxide synthase; ERK1/2, mitogen-activated protein kinase; ICAM-1, intercellular
  adhesion molecule 1; IFNγ, interferon gamma; iNOS, nitric oxide synthase 2; IκB,
  inhibitor of nuclear factor kappa B kinase subunit beta; JAK, Janus kinase 2; LPS,
  lipopolysaccharide; LXRα, nuclear receptor subfamily 1 group H member 3; MMP-9,
  matrix metalloproteinase; NFκB, nuclear factor-kB; Nrf2, nuclear factor, erythroid
  2 like 2; PGC1α, peroxisome proliferator activated receptor gamma coactivator 1
  alpha; SIRT1, sirtuin 1; STAT3, signal transducer and activator of transcription
  3; TLR4, toll-like receptor 4; VCAM-1, vascular cell adhesion molecule 1.'
papertitle: 'C1q/Tumor Necrosis Factor-Related Protein 9: Basics and Therapeutic Potentials.'
reftext: Hua Guan, et al. Front Physiol. 2022;13:816218.
year: '2022'
doi: 10.3389/fphys.2022.816218
journal_title: Frontiers in Physiology
journal_nlm_ta: Front Physiol
publisher_name: Frontiers Media S.A.
keywords: CTRP9 | cardiovascular disease | atherosclerosis | metabolism disease |
  type II diabetes mellitus
automl_pathway: 0.94685
figid_alias: PMC8971810__F4
figtype: Figure
redirect_from: /figures/PMC8971810__F4
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8971810__fphys-13-816218-g004.html
  '@type': Dataset
  description: 'Signaling pathways regulated by CTRP9. CTRP9 binds and affects four
    receptors on the cell membrane and activates downstream signaling pathways: (1)
    LPS binds to membrane receptor CD14 to activate the TLR4 signaling pathway. IκBs
    bind to NFκB to promote the expression of downstream inflammatory genes, including
    MCP-1, TNF-α, ICAM-1, and VCAM-1. CTRP9 blocks the activation of TLR4 receptors
    via LPS. (2) CTRP9 associates with IFNγ to activate the JAK/STAT3 pathway, thus
    upregulating the gene and protein expression of iNOS. (3) CTRP9 associates with
    AdipoR1 to upregulate the SIRT1/PGC1α/AMPK pathway, activate ACC and inhibit the
    expression of nuclear transcription factor NFκB, upregulate LXRα and promote the
    expression of ABCA1, and upregulate ABCG1 to activate Akt, thereby increasing
    eNOS expression; (4) CTRP9 associates with N-cadherin to activate ERK1/2 and upregulate
    MMP-9 and Nrf2. AMPK, AMP-activated protein kinase; CD14, cluster of differentiation
    14; eNOS, endothelial nitric oxide synthase; ERK1/2, mitogen-activated protein
    kinase; ICAM-1, intercellular adhesion molecule 1; IFNγ, interferon gamma; iNOS,
    nitric oxide synthase 2; IκB, inhibitor of nuclear factor kappa B kinase subunit
    beta; JAK, Janus kinase 2; LPS, lipopolysaccharide; LXRα, nuclear receptor subfamily
    1 group H member 3; MMP-9, matrix metalloproteinase; NFκB, nuclear factor-kB;
    Nrf2, nuclear factor, erythroid 2 like 2; PGC1α, peroxisome proliferator activated
    receptor gamma coactivator 1 alpha; SIRT1, sirtuin 1; STAT3, signal transducer
    and activator of transcription 3; TLR4, toll-like receptor 4; VCAM-1, vascular
    cell adhesion molecule 1.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CD14
  - TLR4
  - MYD88
  - TRAF6
  - CCL2
  - TNF
  - ICAM1
  - IFNG
  - STAT3
  - NOS2
  - GATA4
  - CDH2
  - MMP9
  - NR1H3
  - IRF6
  - NDUFA2
  - IRAK1
  - NFKB1
  - CHUK
  - IKBKB
  - IKBKG
  - IKBKE
  - TBK1
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - IFNAR2
  - C1QTNF9
  - CALM2
  - CALM3
  - PICALM
  - SNAP91
  - CALM1
  - ISYNA1
  - AKT1
  - AKT2
  - AKT3
  - NOS3
  - ENO4
  - PPARGC1A
  - PRKAA1
  - PRKAA2
  - PRKAB1
  - PRKAB2
  - PRKAG1
  - PRKAG2
  - PRKAG3
  - ACACA
  - BMS1
  - ACACB
  - MAPK3
  - MAPK1
  - GABPA
  - NFE2L2
  - Tlr4
  - Cd14
  - Mp
  - Myd88
  - Irak1
  - Traf6
  - Nfkb1
  - Mcpt1
  - Ccl2
  - Tnf
  - Icam1
  - Ifng
  - Stat3
  - C1qtnf9
  - Calm1
  - Picalm
  - Nos2
  - Gata4
  - Akt1
  - Nos3
  - Ppargc1a
  - Acc
  - Cdh2
  - Mapk3
  - Mapk1
  - Mmp9
  - Nfe2l2
  - Prkaa2
  - Nr1h3
  - myd88
  - traf6
  - tnfa
  - stat3
  - gata4
  - cdh2
  - mmp9
  - Toll-4
  - Dif
  - dl
  - Rel
  - IKKepsilon
  - key
  - IKKbeta
  - egr
  - hop
  - bsk
  - Inos
  - Nos
  - pnr
  - Akt
  - srl
  - SNF4Agamma
  - AMPKalpha
  - ACC
  - tacc
  - acclinal-wing
  - CadN
  - rl
  - Keap1
  - cnc
  - tnfb
  - ifng1
  - ppargc1a
  - acaca
  - mapk3
  - nfe2l2a
---
